Perrigo to Buy Elan for $8.6 Billion

DUBLIN -- U.S. drugmaker Perrigo ( PRGO) has agreed to buy Ireland's Elan ( ELN) for $8.6 billion in a deal designed to expand overseas and reduce its tax bill.

Michigan-based Perrigo said it will pay Elan investors $6.25 per share in cash and $10.25 in Perrigo stock. The deal represents an 11% premium over Elan's closing price Friday.

Earlier this month, Elan said it was open to offers after spending months fighting a hostile, lower-priced takeover bid by Royal Pharma.

Perrigo said Monday it will become an Irish-based company and said it could cut its tax liabilities nearly in half, saving more than $150 million annually.

About 700 U.S. companies based in Ireland pay a 12.5% rate of tax on profits, versus the U.S. rate of 35%.

Elan confirmed the deal.
Copyright 2011 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

If you liked this article you might like

Incoming Perrigo CEO Brings Strong Operations Experience

Incoming Perrigo CEO Brings Strong Operations Experience

These Are the Biggest Winners and Losers in Activist Investing This Year

These Are the Biggest Winners and Losers in Activist Investing This Year

McDonald's Takes Bite Out of Dow, but Nasdaq and S&P 500 at Records

McDonald's Takes Bite Out of Dow, but Nasdaq and S&P 500 at Records

Perrigo Stock Jumps as Starboard's Smith Says Generic Drugs a Strong Business

Perrigo Stock Jumps as Starboard's Smith Says Generic Drugs a Strong Business

Valeant CEO Confident Divestitures Can Successfully Pare Debt, Skeptics Remain

Valeant CEO Confident Divestitures Can Successfully Pare Debt, Skeptics Remain